Stock EWTX EDGEWISE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Real-time Estimate Cboe BZX
Other stock markets
 19:32:59 29/04/2024 BST 		5-day change 1st Jan Change
16.96 USD +4.92% Intraday chart for Edgewise Therapeutics, Inc. +13.76% +56.81%
04-23 Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU MT
04-22 RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
Edgewise Therapeutics Full Year 2023 Net Loss Widens
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy
Edgewise Therapeutics Insider Sold Shares Worth $596,805, According to a Recent SEC Filing
Edgewise Therapeutics Insider Sold Shares Worth $1,419,759, According to a Recent SEC Filing
Edgewise Therapeutics Insider Bought Shares Worth $4,999,995, According to a Recent SEC Filing
Top Midday Gainers
Edgewise Therapeutics Surging After Pricing $240 Million Stock Sale Above Last Close
Edgewise Therapeutics Insider Sold Shares Worth $1,610,097, According to a Recent SEC Filing
Edgewise Says US FDA Grants Orphan Drug, Rare Pediatric Disease Designations for Investigational Muscular Dystrophy Therapy
Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Edgewise Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Edgewise Therapeutics Expands Duchenne Muscular Dystrophy Clinical Program
Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy
Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy
Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EWTX Stock
  4. News Edgewise Therapeutics, Inc.
  5. Other languages